Oncternal Therapeutics, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

SEC Insider

$124.8M

1,587 transactions

Summary

Oncternal Therapeutics, Inc. is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $58.7MSales: $27.7M49 insiders

Date	Insider	Type	Value
2024-03-28	Wills Robert James	Buy	$59K
2024-04-08	Wills Robert James	Buy	$28K
2024-01-03	BREITMEYER JAMES B(Chief Executive Officer)	F	$25K
2024-02-23	Wills Robert James	Sell	$9K
2024-02-23	HALE DAVID F	Buy	$6K
2024-02-23	HALE DAVID F	Buy	$2K
2024-06-20	MAZANET ROSEMARY	A	$0
2024-06-20	HALE DAVID F	A	$0
2024-06-20	LARUE WILLIAM R	A	$0
2024-06-20	Wills Robert James	A	$0
2024-06-20	CARTER MICHAEL G	A	$0
2024-06-20	KISNER DANIEL L	A	$0
2024-06-20	DeSimone Jill	A	$0
2024-06-20	THEUER CHARLES	A	$0
2024-02-14	VINCENT RICHARD G(Chief Financial Officer)	A	$0
2024-02-14	Yazji Salim(Chief Medical Officer)	A	$0
2024-02-14	Krishnan Rajesh(CTO/CSO)	A	$0
2024-02-14	Leavitt Chase C.(General Counsel/Secretary)	A	$0
2024-02-14	BREITMEYER JAMES B(Chief Executive Officer)	A	$0
2024-02-14	BREITMEYER JAMES B(Chief Executive Officer)	A	$0

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Oncternal Therapeutics, Inc. — Contributions, Lobbying & Contracts | Poliscope